One simple blood test that screens for up to 55 cancer types — powered by advanced metabolomics and AI analysis. Introducing OncoVeryx™ , available through Medivexa Labs.
Many cancers show little or no symptoms until they have progressed — by the time they are found, treatment options can be limited.
Early detection can play a critical role in improving treatment options and health outcomes.
Proactive screening matters even when you feel perfectly healthy.
A broader screen means fewer blind spots across cancer types.
Conventional methods are often limited to specific cancer types — one test, one cancer — leaving many others unmonitored.
A single blood test that screens for multiple cancers at once — supporting a far more proactive view of your health.
An innovative blood-based MCED test that analyses biological signatures in the blood to identify patterns associated with cancer. Tap a step to explore.
OncoVeryx™ screens for a broad spectrum of cancers. Search the list:
No match in the named list — covers up to 55 types. Ask our team →
…and many more — covering up to 55 cancer types through a single blood test.
At Medivexa Labs, we are committed to bringing innovative diagnostic solutions that combine scientific excellence, authenticity, and advanced technology.
We partner with leading healthcare innovators to provide access to next-generation diagnostic tests that empower informed healthcare decisions.
Our focus is on delivering reliable, high-quality diagnostic services — helping individuals take charge of their health through early detection and preventive screening.
OncoVeryx is a simple blood test that helps identify multiple types of cancer at an early stage, particularly in individuals at higher risk or those who may not show symptoms. The test is noninvasive (requiring only a simple blood draw) and a proven accuracy rate of 98%, making it a valuable tool for doctors in timely diagnosis to enhance patient care.
In clinical studies, OncoVeryx demonstrated a strong performance, achieving 98% average accuracy, 98% sensitivity, and 99% specificity.
Through a simple blood sample collection — no scans and no complex preparation. Our team can guide you through the process when you enquire.
For selected cancer types, the test can indicate where in the body a detected cancer-associated signal may have originated — helping guide further clinical evaluation with your doctor.
No. OncoVeryx™ is a screening test and is not intended to replace physician consultation, routine cancer screening programs, or diagnostic procedures. Clinical decisions should always be made with a qualified healthcare professional.
A positive result does not confirm the presence of cancer and should be followed by further medical evaluation. A negative result does not completely rule out the possibility of cancer.
Reach out to our team by phone, email, or the enquiry form below — we'll be happy to assist with eligibility, the collection process, and pricing.
OncoVeryx™ is a screening test and is not intended to replace physician consultation, routine cancer screening programs, or diagnostic procedures.
A positive result does not confirm the presence of cancer and should be followed by further medical evaluation. A negative result does not completely rule out the possibility of cancer. Clinical decisions should always be made in consultation with a qualified healthcare professional.
Questions about eligibility, the sample collection process, or pricing? Our team will be happy to assist you.